Gravity Analytica

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NRBO 11.13.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-14

Name of Upcoming Event:Life Science Virtual Investor Forum

Date of Upcoming Event:2024-11-21

Name of Upcoming Event:Winter 2024 Investor Summit Virtual

Full Press Release SEC Filings Our NRBO Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.,Nov. 13, 2024/PRNewswire/ --NeuroBo Pharmaceuticals, Inc.(Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November:

November 14:Life Science Virtual Investor Forum.Hyung Heon Kim, President and Chief Executive Officer andMarshall H. Woodworth, Chief Financial Officer, will present a company overview onThursday, November 14, at1:00 pm ET. Management will also be available for one-on-one meetings during the event. Interested parties who would like to listen to the Company's presentation or request a meeting can do so after registering for the conference athttps://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-6.
November 21:Winter 2024 Investor Summit Virtual.Mr. KimandMr. Woodworthwill present a company overview onThursday, November 21, at11:00 am ET, at this virtual summit. To listen to the presentation or to schedule one-on-one meetings, interested parties can register at:https://www.webcaster4.com/Webcast/Page/3075/51588.

To schedule a meeting with management outside of these events, investors can contactMichael Milleratmmiller@rxir.com.

AboutNeuroBo PharmaceuticalsNeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visitwww.neurobopharma.com.

Contacts:

NeuroBo PharmaceuticalsMarshall H. WoodworthChief Financial Officer+1-857-299-1033marshall.woodworth@neurobopharma.com

Rx Communications GroupMichael Miller+1-917-633-6086mmiller@rxir.com

View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-investor-conferences-in-november-302303033.html

SOURCENeuroBo Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com